The publication of a fully standardized protocol for the PATHFAST TB LAM Ag assay marks a notable shift in how tuberculosis treatment response can be measured at the laboratory bench. Protocols of this kind matter because reproducibility has long been a weak point in the translation of diagnostic assays from validation studies into routine practice. By documenting every pre-analytical step, from sputum collection through heat inactivation to the automated chemiluminescent readout, the authors give laboratories a common reference point against which their own implementation can be checked, audited, and compared. This is particularly important for an assay intended to be used serially in individual patients, where small procedural variations can otherwise be mistaken for genuine changes in bacterial burden.

The choice of lipoarabinomannan as the target analyte is central to the assay’s logic. LAM is a cell-wall glycolipid found only in mycobacteria, which gives it a high degree of biological specificity for the Mycobacterium tuberculosis complex. Unlike nucleic acid targets, which can persist after bacteria have been killed by effective therapy, LAM is shed from bacterial cells and its concentration in sputum reflects the burden of actively releasing organisms. This makes it a naturally dynamic marker: as treatment takes effect and bacterial numbers fall, the amount of LAM detectable in sputum declines in parallel. The published clinical evaluation cited in the protocol captured this behavior directly, showing that reductions in LAM concentration mirrored the declines seen in culture results while being available in a fraction of the time.

The analytical specifications reported for the assay are worth examining in detail because they define the range of clinical situations in which it can be used. A detection limit of 6.67 pg/mL is low enough to detect residual antigen in samples from patients whose bacterial load has been driven down substantially by therapy, which is precisely the situation in which treatment monitoring matters most. The linear measurement range of 10.0 to 50,000 pg/mL spans more than three orders of magnitude, accommodating sputum samples from patients with very heavy bacillary loads at diagnosis through to those approaching cure. A wide dynamic range of this kind reduces the need for sample dilution and repeat testing, which in turn shortens turnaround and lowers cost per actionable result.

The clinical performance figures reported in the validation work place the assay in a competitive position relative to existing tools. Sensitivity of 88.8 percent, with a 95 percent confidence interval running from 80.0 to 94.0 percent, indicates that the assay detects the large majority of culture-positive cases when used for diagnostic purposes. Specificity of 100 percent, with a lower confidence bound of 83.9 percent, suggests that false positives are rare, which matters greatly in settings where a positive result triggers lengthy and potentially toxic multidrug therapy. These figures were generated against mycobacterial culture, the traditional reference standard, and the strong correlation observed between LAM concentration and bacterial load provides additional reassurance that the assay is measuring something biologically meaningful rather than merely detecting the presence or absence of antigen.

The heat inactivation step deserves particular attention because it addresses one of the most persistent operational barriers to TB testing outside of specialized laboratories. Mycobacterium tuberculosis is a biosafety concern that traditionally requires Biosafety Level 3 containment for culture work, and even sputum handling for smear microscopy carries infection risk for laboratory staff. Heating samples at 100 degrees Celsius for 20 minutes renders them non-infectious while preserving the LAM antigen for detection, which means the assay can be performed on a bench-top analyzer in laboratories that lack high-containment infrastructure. This has practical consequences for where the test can be deployed: district hospitals, regional laboratories, and research facilities in high-burden countries can all consider adoption without the capital investment that culture facilities demand.

The contrast with culture-based monitoring is instructive when thinking about the practical value of the assay. Culture remains the reference standard for assessing treatment response, but it suffers from contamination rates that the protocol cites as ranging from 4.2 to 9.6 percent of results being invalid. An invalid culture result means the patient must provide another sample and wait additional weeks for a usable answer, which is a real cost in terms of clinical decision-making and patient retention in care. The PATHFAST TB LAM Ag assay, by contrast, consistently produces valid results because it does not depend on the viability of organisms in the sample or on the sterility of the culture medium. This reliability advantage compounds over the course of a treatment program, where multiple monitoring points per patient are the norm.

The one-hour turnaround time is another dimension in which the assay differs meaningfully from existing options. Smear microscopy, although fast, lacks the sensitivity to detect the low bacterial loads that characterize later stages of treatment, with reported sensitivity in the range of 50 to 60 percent in many settings. Molecular assays such as Xpert MTB/RIF are rapid but are designed primarily for diagnosis rather than monitoring, because the DNA they target can persist in non-viable organisms and therefore does not reliably distinguish active infection from residual genetic material. Culture, the most informative existing option, requires two to eight weeks before results are available. A quantitative result available within one hour of sample collection opens the possibility of same-visit clinical decision-making, which is a fundamentally different workflow from the current model of sending samples away and reviewing results at subsequent appointments.

The protocol’s alignment with the World Health Organization’s Target Product Profiles for TB treatment monitoring tests is worth noting because it situates the assay within a broader policy framework. The WHO’s End TB Strategy calls for a 90 percent reduction in TB incidence and a 95 percent reduction in deaths by 2035, goals that depend on better tools across the entire care cascade. Treatment monitoring has been identified as a particular gap, because the tools currently available either lack the sensitivity to detect meaningful change or take too long to produce results that can influence clinical decisions. An assay that meets the TPP criteria for rapidity, quantification, and operational simplicity is therefore not just a laboratory convenience but a component of the global strategy to bring the epidemic under control.

The burden of tuberculosis falls disproportionately on low- and middle-income countries, which account for more than 80 percent of all cases according to the WHO Global Tuberculosis Report 2025. That report estimates 10.7 million new cases and 1.23 million deaths in 2024, figures that underscore the scale of the problem and the urgency of deploying better monitoring tools where they are most needed. Any assay intended for use in these settings must be affordable, robust, and simple enough to be operated by staff with general laboratory training rather than specialized mycobacteriology expertise. The PATHFAST platform, being a bench-top automated analyzer, is designed with these constraints in mind, and the protocol’s emphasis on standardized sample handling and automated measurement reflects an awareness that human operational variability is often the limiting factor in real-world performance.

The position of the PATHFAST TB LAM Ag assay within the current landscape of quantitative TB monitoring tools is also notable. According to the Treatment Action Group’s 2025 Pipeline Report, it is currently the only commercially available quantitative bacterial load monitoring tool for tuberculosis. The closest molecular comparator, the Molecular Bacterial Load Assay, targets 16S rRNA and offers a viability-linked signal with a wide dynamic range, but it remains in late-stage development, requires an approximately four-hour workflow at the district laboratory level, and is not yet commercially available. This means that, for the present, clinicians and researchers who need quantitative bacterial load data have essentially one commercial option, which makes the availability of a validated protocol for that option all the more consequential for trial design and clinical practice alike.

The relevance of rapid quantitative monitoring extends beyond individual patient care into the domain of drug development. Clinical trials of new tuberculosis regimens traditionally rely on culture conversion at two months and sustained culture negativity thereafter as primary endpoints, which means trials must run for many months to capture meaningful signals. A biomarker that declines in proportion to bacterial load and can be measured within an hour offers the possibility of earlier pharmacodynamic readouts, potentially shortening the duration of early-phase trials and reducing the cost of bringing new regimens to patients. The strong correlation between sputum LAM concentration and bacterial load observed in the clinical evaluation suggests that the assay could serve this purpose, although the protocol itself is focused on laboratory implementation rather than trial design.

The pre-analytical phase of the assay, which the protocol addresses in detail, is often where the greatest variability enters diagnostic workflows. Sputum quality, collection timing, storage conditions, and transport all influence the concentration of detectable antigen before the sample ever reaches the analyzer. By specifying validated requirements for each of these steps, the protocol reduces the sources of variation that would otherwise complicate the interpretation of serial measurements in a single patient. This is particularly important for treatment monitoring, where the clinical question is not whether a single result exceeds a threshold but whether the trend over time indicates a response to therapy. Consistency in pre-analytical handling is therefore not a minor technical detail but a prerequisite for the assay to function as a monitoring tool rather than merely a diagnostic one.

The two-level calibrator set and daily quality control materials specified in the protocol reflect standard immunoassay practice but carry particular weight in a quantitative monitoring context. Because treatment decisions may hinge on whether a patient’s LAM concentration has fallen by a meaningful margin between visits, the accuracy and consistency of the standard curve across days and operators directly affects clinical interpretation. The inclusion of a master calibration entry card for the analyzer further standardizes the measurement process across laboratories, which is a prerequisite for comparing results between sites in multi-center studies or for building the evidence base needed for future guideline recommendations.

The fact that the assay is described as likely applicable to biological samples beyond sputum, while sputum remains the primary validated matrix, points toward future research directions. Urine-based LAM tests have already proven useful for diagnosing tuberculosis in people living with HIV, and the possibility of quantitative LAM measurement in other specimen types could expand the assay’s utility to patients who cannot produce sputum or who have extrapulmonary disease. However, the protocol is careful to ground its claims in the evidence currently available, and the clinical performance figures cited apply specifically to sputum samples compared against culture. Extending the assay to other matrices would require separate validation, and the protocol’s restraint on this point is appropriate for a methods paper intended to guide real-world implementation.

Taken together, the protocol represents a deliberate effort to move a promising analytical tool from the validation study into routine and research practice by removing the ambiguity that often accompanies new assay adoption. The combination of rapid turnaround, quantitative output, wide dynamic range, low biosafety requirements, and consistent validity positions the PATHFAST TB LAM Ag assay to address a genuine gap in the tuberculosis care cascade. Whether it fulfills that potential at scale will depend on factors the protocol cannot itself resolve, including cost, supply chain reliability, and the willingness of national programs to incorporate quantitative antigen monitoring into their treatment guidelines. What the protocol does provide is the technical foundation on which those larger questions can now be systematically addressed.

Subject of Research: A rapid blood-based biomarker assay for detecting concussion

Article Title: The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring

Article References: Shuaib, Y. A., & Coisne, S. (2026). The PATHFAST TB LAM Ag assay: a validated protocol for quantitative tuberculosis treatment monitoring. Frontiers in Antibiotics, 5, Article 1844052. https://doi.org/10.3389/frabi.2026.1844052

Image Credits: AI Generated

DOI: 10.3389/frabi.2026.1844052

Keywords: concussion, blood test, biomarkers, traumatic brain injury, diagnostics, sports medicine, emergency medicine, point-of-care testing, PATHFAST, assay, validated, protocol